Article | June 17, 2020

Updated US FDA Guidance For The Gene Therapy Industry: Key Changes And Areas Of Increased Focus

By Leyla Diaz, Ph.D., Senior Technical Specialist, Biosafety Testing Services, Rockville, MD

gene therapy

In January 2020, the United States Food and Drug Administration (FDA) released several new or updated guidance documents pertaining to human gene therapy products. The guidance documents address product development and clinical trial design in general, as well as for specific disease indications. Two guidance documents that address product development, safety and characterization are:

  • Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up, which supersedes the guidance published in 2006
  • Chemistry, Manufacturing and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), which supersedes the guidance published in 2008

Several key changes that will impact developers of gene therapies are summarized below.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: